Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
Biomed Res Int. 2020 Nov 24;2020:4029062. doi: 10.1155/2020/4029062. eCollection 2020.
Triple-negative breast cancer (TNBC) is usually poorly differentiated, highly invasive, susceptible to distant metastasis, and less responsive to endocrine and targeted therapy. However, immunotherapy is a promising treatment for TNBC patients recently.
The prognostic value of immune-related genes (IRGs) was explored by using RNA sequencing and microarray data of 123 and 107 TNBC patients from TCGA and GEO databases, respectively.
In TCGA database, GO and KEGG pathway analysis of 119 differential IRGs indicated that they actively participate in the interaction of cytokines and receptors. A nomogram model constructed by the prognosis-related CCL25, IL29, TDGF3, GPR44, and GREM2 in the IRGs could personalize and visualize the 1-, 2-, 3-, 4-, and 5-year overall survival (OS) of TNBC patients. Moreover, TNBC patients could be defined as low-risk (risk score < 194) or high-risk (risk score ≥ 194) cohorts based on the risk score derived from the nomogram model. The results could be validated by the GSE58812 dataset. Furthermore, the risk score was an independent risk factor for TNBC patients (HR = 1.019, 95% CI 1.012-1.027, < 0.001) and was positively related to stage ( = 0.017). Interestingly, the risk score could reflect the infiltration of B cells, CD4+ T cells, CD8+ T cells, dendritic cells, and neutrophils.
These findings provided a reference for personalized OS prediction in TNBC patients and might be potential immune biomarkers for designing novel therapy.
三阴性乳腺癌（TNBC）通常分化较差、侵袭性高、易发生远处转移，对内分泌和靶向治疗反应不佳。然而，免疫疗法最近是 TNBC 患者的一种有前途的治疗方法。
分别使用来自 TCGA 和 GEO 数据库的 123 名和 107 名 TNBC 患者的 RNA 测序和微阵列数据来探索免疫相关基因（IRGs）的预后价值。
在 TCGA 数据库中，119 个差异 IRGs 的 GO 和 KEGG 通路分析表明，它们积极参与细胞因子和受体的相互作用。IRGs 中与预后相关的 CCL25、IL29、TDGF3、GPR44 和 GREM2 构建的列线图模型可以个性化和可视化 TNBC 患者的 1、2、3、4 和 5 年总生存率（OS）。此外，根据列线图模型得出的风险评分，TNBC 患者可分为低风险（风险评分<194）或高风险（风险评分≥194）队列。该结果可以通过 GSE58812 数据集进行验证。此外，风险评分是 TNBC 患者的独立危险因素（HR=1.019，95%CI 1.012-1.027，<0.001），与分期呈正相关（=0.017）。有趣的是，风险评分可以反映 B 细胞、CD4+T 细胞、CD8+T 细胞、树突状细胞和中性粒细胞的浸润情况。
这些发现为 TNBC 患者的个性化 OS 预测提供了参考依据，可能是设计新疗法的潜在免疫生物标志物。
